Fenretinide: A novel treatment for endometrial cancer

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Mittal, Navdha ^a   Malpani, Saurabh ^a   Dyson, Matthew ^a   Ono, Masanori ^a   Coon, John S ^a   Kim, Julie J ^a   Schink, Julian C ^a,b   Bulun, Serdar E ^a   Pavone, Mary Ellen ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SPECTRUM HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CELL SURFACE RECEPTOR; CELLULAR RETINOL BINDING PROTEIN 1; FENRETINIDE; KI 67 ANTIGEN; MEGESTROL ACETATE; MESSENGER RNA; PROTEIN STRA6; RETINOIC ACID RECEPTOR; RETINOL; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; STRA6 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENDOMETRIAL CANCER CELL LINE; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; ISHIKAWA CELL; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; VITAMIN METABOLISM; ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; ENDOMETRIAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; FEMALE; FENRETINIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MEGESTROL ACETATE; MEMBRANE PROTEINS; MICE, NUDE; VITAMIN A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908409235     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110410     Document Type: Article

References (42)

1. Society AC (May 2, 2013) Cancer Facts and Figures 2013, American Cancer Society, Atlanta, Ga
2. Pant A (2012) Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin. http://wwwcancerorg/cancer/endometrialcancer/overviewguide/endometrial-uterine-cancer-overview-key-statistics.
3. Howlader N, Noone AM, Yu M, Cronin KA (2012) Use of imputed population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer. Am J Epidemiol 176: 347-356.
4. Myatt SS, Wang J, Monteiro L.J., Christian M., Ho KK, et al. (2010) Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 70: 367-377.
5. Ray M, Fleming G (2009) Management of advanced-stage and recurrent endometrial cancer. Semin Oncol 36: 145-154.
6. Kim JJ, Chapman-Davis E (2010) Role of progesterone in endometrial cancer. Semin Reprod Med 28: 81-90.
7. Kim JJ, Kurita T, Bulun SE (2013) Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev 34: 130-162.
8. Cheng YH, Utsunomiya H, Pavone M.E., Yin P., Bulun SE (2011) Retinoic acid inhibits endometrial cancer cell growth via multiple genomic mechanisms. J Mol Endocrinol 46: 139-153.
9. Hu Y, Liu HX, He Y, Fang Y., Fang J, et al. (2013) Transcriptome profiling and genome-wide DNA binding define the differential role of fenretinide and alltrans RA in regulating the death and survival of human hepatocellular carcinoma Huh7 cells. Biochem Pharmacol 85: 1007-1017.
10. Choi Y, Kim SY, Kim S.H., Yang J., Park K, et al. (2003) Inhibition of tumor growth by biodegradable microspheres containing all-trans-retinoic acid in a human head-and-neck cancer xenograft. Int J Cancer 107: 145-148.
11. Di C, Liao S, Adamson D.C., Parrett TJ, Broderick DK, et al. (2005) Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res 65: 919-924.
12. Kawaguchi R, Yu J, Honda J., Hu J, Whitelegge J, et al. (2007) A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. Science 315: 820-825.
13. Pavone ME, Reierstad S, Sun H., Milad M, Bulun SE, et al. (2010) Altered retinoid uptake and action contributes to cell survival in endometriosis. J Clin Endocrinol Metab 95: E300-309.
14. Cheng YH, Yin P, Xue Q., Yilmaz B, Dawson MI, et al. (2008) Retinoic acid (RA) regulates 17beta-hydroxysteroid dehydrogenase type 2 expression in endometrium: interaction of RA receptors with specificity protein (SP) 1/SP3 for estradiol metabolism. J Clin Endocrinol Metab 93: 1915-1923.
15. Bastien J, Rochette-Egly C (2004) Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 328: 1-16.
16. Deng L, Shipley GL, Loose-Mitchell DS, Stancel G.M., Broaddus R., et al. (2003) Coordinate regulation of the production and signaling of retinoic acid by estrogen in the human endometrium. J Clin Endocrinol Metab 88: 2157-2163.
17. Cazzaniga M, Varricchio C, Montefrancesco C., Feroce I, Guerrieri-Gonzaga A (2012) Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk? J Biomed Biotechnol 2012: 172897.
18. Cooper JP, Hwang K, Singh H., Wang D, Reynolds CP, et al. (2011) Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure. Br J Pharmacol 163: 1263-1275.
19. Delia D, Aiello A, Lombardi L., Pelicci PG, Grignani F, et al. (1993) N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 53: 6036-6041.
20. Kalemkerian GP, Slusher R, Ramalingam S., Gadgeel S, Mabry M (1995) Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. J Natl Cancer Inst 87: 1674-1680.
21. Mariotti A, Marcora E, Bunone G., Costa A, Veronesi U, et al. (1994) N-(4-hydroxyphenyl)retinamide: a potent inducer of apoptosis in human neuroblas-toma cells. J Natl Cancer Inst 86: 1245-1247.
22. O'Donnell PH, Guo WX, Reynolds C.P., Maurer BJ (2002) N-(4-hydroxyphe-nyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia 16: 902-910.
23. Oridate N, Lotan D, Xu X.C., Hong WK, Lotan R (1996) Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2: 855-863.
24. Veronesi U, Mariani L, Decensi A., Formelli F, Camerini T, et al. (2006) Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17: 1065-1071.
25. Sabichi AL, Lerner SP, Atkinson E.N., Grossman HB, Caraway NP, et al. (2008) Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res 14: 224-229.
26. Chiesa F, Tradati N, Grigolato R., Boracchi P, Biganzoli E, et al. (2005) Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int J Cancer 115: 625-629.
27. Children's Oncology G, Villablanca JG, Krailo MD, Ames MM, Reid JM, et al. (2006) Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 24: 3423-3430.
28. Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, et al. (2003) Phase I trial and pharmacokinetics of fenretinide in children with neuroblas-toma. Clin Cancer Res 9: 2032-2039.
29. Puduvalli VK, Yung WK, Hess K.R., Kuhn JG, Groves MD, et al. (2004) Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol 22: 4282-4289.
30. Vaishampayan U, Heilbrun LK, Parchment R.E., Jain V., Zwiebel J, et al. (2005) Phase II trial of fenretinide in advanced renal carcinoma. Invest New Drugs 23: 179-185.
31. Reynolds CP FT, Tsao-Wei D, Groshen S., Morgan R, McNamara M et al. High plasma levels of fenretinide (4-HPR) were associated with improved outcome in a phase II study of recurrent ovarian cancer: a study by the California Cancer Consortium.; 2007.
32. Nishida M (2002) The Ishikawa cells from birth to the present. Hum Cell 15: 104-117.
33. Invitrogen (2012) "PrestoBlue cell viability reagent protocol," Product information sheet by Life Technologies".
34. Ma JJ, Monsivais D, Dyson M.T., Coon JS, Malpani S, et al. (2013) Ligand-activated peroxisome proliferator-activated receptor beta/delta modulates human endometrial cancer cell survival. Horm Cancer 4: 358-370.
35. Pant A, Lee, II, Lu Z., Rueda BR, Schink J, et al. (2012) Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin. PLoS One 7: e41593.
36. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
37. Formelli F, Cleris L (2000) Therapeutic effects of the combination of fenretinide and all-trans-retinoic acid and of the two retinoids with cisplatin in a human ovarian carcinoma xenograft and in a cisplatin-resistant sub-line. Eur J Cancer 36: 2411-2419.
38. Carrera S, Cuadrado-Castano S, Samuel J., Jones GD, Villar E, et al. (2013) Stra6, a retinoic acid-responsive gene, participates in p53-induced apoptosis after DNA damage. Cell Death Differ 20: 910-919.
39. Ulukaya E, Pirianov G, Kurt M.A., Wood EJ, Mehmet H (2003) Fenretinide induces cytochrome c release, caspase 9 activation and apoptosis in the absence of mitochondrial membrane depolarisation. Cell Death Differ 10: 856-859.
40. Holmes WF, Soprano DR, Soprano KJ (2004) Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines. J Cell Physiol 199: 317-329.
41. Bonanni B, Lazzeroni M (2009) Retinoids and breast cancer prevention. Recent Results Cancer Res 181: 77-82.
42. Zhao S, Li G, Yang L., Li L, Li H (2013) Response-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetate. Oncol Lett 5: 139-144.